Vamil Divan

In a report published Friday, Credit Suisse analyst Vamil Divan reiterated an Outperform rating on Bristol-Myers Squibb (NYSE: BMY), and raised the price target from $56.00 to $60.00. In the report, Credit Suisse noted, “Details of BMY's divestiture of its stake in its diabetes joint venture (JV)...

In a report published Monday, Credit Suisse analyst Vamil Divan downgraded the rating on Myriad Genetics (NASDAQ: MYGN) from Neutral to Underperform, and lowered the price target from $28.00 to $20.00. In the report, Credit Suisse noted, “We downgrade MYGN to Underperform (from Neutral) and lower...